From the MDS Beacon
Velcade-Cytarabine Combination Shows Promise For Certain Higher-Risk MDS Patients
by Jessica Langholtz
According to a recent Phase 1/2 study conducted in Europe, the combination of Velcade and cytarabine may be effective and safe in higher-risk myelodysplastic syndromes patients who have not been previously treated.
In addition, the combination showed activity in patients with unfavorable chromosomal abnormalities. Specifically, 13 percent of these patients responded, which the investigators describe as notable, since no patients with these types of chromosomal abnormalities responded in previous studies testing cytarabine alone.
For the rest, see the article at MDS Beacon.